Tissue Regenix Group plc (AIM: TRX)

Market Cap	41.67M
Revenue (ttm)	25.16M
Net Income (ttm)	-871.19K
Shares Out	71.23M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	243.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,296
Average Volume	25,359
Open	57.00
Previous Close	58.50
Day's Range	57.00 - 59.25
52-Week Range	51.00 - 75.00
Beta	1.62
RSI	49.73
Earnings Date	Mar 14, 2025

About Tissue Regenix Group

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 82
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: TRX

Financial Performance

In 2023, Tissue Regenix Group's revenue was $29.49 million, an increase of 20.50% compared to the previous year's $24.48 million. Losses were -$1.71 million, -36.44% less than in 2022.

Financial numbers in USD